

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

KVK-TECH, INC.,

Petitioner,

v.

SHIRE LLC,

Patent Owner.

Case IPR2018-00290
US Patent No. 8,846,100

PATENT OWNER SUR-REPLY

TABLE OF CONTENTS

	Page
I. Summary of Patent Owner’s Argument	1
II. No Motivation or Reasonable Expectation of Success	2
A. Petitioner Has Not Shown that Acute Tolerance Would Be Disregarded by a POSA Faced With Shojaei’s Objectives.....	2
B. Petitioner Has Not Shown that GI Barriers Would Be Disregarded by a POSA Faced With Shojaei’s Objectives.....	9
C. The Prior Art Taught Away from the Invention	12
III. No Claims are Inherently Obvious	13
IV. Two Points: Dosage Claims and Objective Evidence	15

LIST OF EXHIBITS

2001	DECLARATION OF BERNHARDT L. TROUT, Ph.D. (with CV)
2002	DECLARATION OF SARA ROSENBAUM, Ph.D. (with CV)
2003	FDA Orange Book Listing for MYDAYIS® (NDA N022063)
2004	MYDAYIS® FDA Label (06-2017)
2005	MYDAYIS® Website Pages
2006	Amidon, U.S. Patent No. 5,229,131
2007	Mehta, U.S. Patent No. 5,837,284
2008	IPR2017-00011 Decision Denying Institution (RE41, 148 (300 Patent)
2009	Excerpts from Merck, 11th Ed
2010	Ansel, Popovich & Allen 6th, Ch. 3-5 (1995)
2011	Sonsalia, Remington Ch. 74, - CNS Stimulants (1995)
2012	Robinson, Remington, Ch. 94 - Sustained Release (1995)
2013	Porter, Remington, Ch. 93 – Coating (1995)
2014	Franz, Remington Vol. II, Ch. 57 - Sympathomimetic Drugs (1995)
2015	Malinowski, Remington, Ch. 53 – Bioequivalence (2000)
2016	Stempel, 7th Ed. - Dispensing of Medication (1971)
2017	USP 23 NF 18 - Uniformity Sec. 905 (1955)
2018	USP 23 NF 18 1995 - Excerpts (1955)
2019	Patrick, Human Psychopharmacology, 12:527-546 (1997)
2020	Spencer, Arch Gen Psych, 58:775-78 (2001 Aug)
2021	Lehninger, Principles of Biochemistry, Excerpt (1993)
2022	Benet, Toxicologic Pathology, 23:115-123 (1995)
2023	Shargel, Applied Bio & Pharmacokinetics, Ch. 2, 10 (1999)
2024	Gibaldi, Biopharmaceutics & Clinical Pharmacokinetics, Ch.1 (1991)
2025	Gibaldi, Biopharmaceutics & Clinical Pharmacokinetics, Ch.5 (1991)
2026	Chiao, Remington, Ch. 94 – Sustained Release (1995)
2027	Hinsvark, J. Pharmacokin. Biopharm., 1:319-328 (1973)
2028	Benet, Transplantation Proc., 31 (Suppl 3A), 7S-9S (1999)
2029	Winters, Basic Clinical Pharmacokinetics (1994)

2030	Rowland, Clinical Pharmacokinetics 2d (1989)
2031	Mircioiu, Basic & Clinical Pharmacology & Toxicology, 96:262–264 (2005)
2032	Booijink, Future Microbiol. 2(3), 285-295 (2007)
2033	Fischer, Pharm. Res., 4:480-485 (1987)
2034	Gupta and Robinson, Controlled Release Delivery (1992)
2035	Macheras, Oral Drug Absorption, Ch. 6 - Modeling Biopharm. (2006)
2036	Schug, European J. Pharm. Sci., 15:279-285 (2002)
2037	Hendeles, J. Allergy Clin. Immunol., 72:7:43-751 (1986)
2038	FDA Use & Limitations of In Vitro Testing (Excerpts)
2039	Guidance for Industry ER Formulations IVIVC (1997)
2040	Amidon, Mol. Pharm., 7:1361 (2010)
2041	Khan, International Journal of Pharmaceutics 140:131-143 (1996)
2042	Koziolk, Advanced Drug Delivery Reviews 101:75–88 (2016)
2043	Chasseaud, Ann. Rev. Pharmacol., 14:35-46 (1974)
2044	Greenhill, J. Am. Acad. Child Adolesc. Psychiatry, 42:1234-1241 (2003)
2045	Swanson, Clin. Pharmacol. Therap., 66:95-305 (1999)
2046	Spencer, Current Diagn & Treatment Psych., Ch 35 – ADHD (2008)
2047	Decision re Institution of IPR2015-02009
2048	Gibaldi, Biopharmaceutics & Clinical Pharmacokinetics, Ch. 7 – (1991)
2049	Gibaldi, Biopharmaceutics & Clinical Pharmacokinetics, Appendix II (1991)
2050	Percel, US 2003-0157173A1
2051	Couch, WO 2004-028509A1
2052	Shire, Q3 2017 MYDAYIS Results (Excerpts)
2053	Brauer, J. Clin. Pharm. 16-1, 72-76 (1996)
2054	Shire, ER and IR Utilization in Adult ADHD [CONFIDENTIAL]
2055	Shire, MYDAYIS Performance [CONFIDENTIAL]
2056	Auiler, Curr. Med. Res. Opin., 18:311-316 (2002)
2058	Ansel, Popovich & Allen 6th, Ch. 3-5 (1995) (adds pages 17-25 to EX2010)
2059	Brauer J. Clin. Pharm. 16-1 72-76 (1996) (replaces missing p.74 of EX2053)
2060	DECLARATION OF JAMES POLLI (with CV)
2061	Swanson, Canadian Child Adolesc. Psych. Re. 1 4-3 (2005)

2062	Goodman & Gilman, 9th ed. (1996), Preface
2063	Remington, 20th ed. (2000), Pharmaceutical Care
2064	Handbook of Pharmaceutical Excipients, 4th ed (2003), Preface
2065	Brown, J. Am. Acad. Child Psych. (19) 225-239 (1980)
2066	Jusko Deposition Exhibit. 304, Levy, Case History of a Pharmaceutical Formulation Failure, Clinical Pharmacology & Therapeutics, 8(6)
2067	Jusko Deposition Exhibit 305, Findling, First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents, Journal of Psychopharmacology, 30(4):404-410 (2010)
2068	Jusko Deposition Exhibit 307, Jusko, SYSTEMS PHARMACOLOGY AND PHARMACODYNAMICS, Foundations of Pharmacodynamic Systems analysis, 161-175 (2016)
2069	Jusko Deposition Exhibit 309, Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring, Guidelines for Collection and Analysis of Pharmacokinetic Data, 8-29 (2006)
2070	JUSKO DEPOSITION TRANSCRIPT (September 27, 2018)
2071	BURGESS DEPOSITION TRANSCRIPT (September 24, 2018)
2072	Burgess Deposition Exhibit 200 (Statement regarding drug doses)
2073	Jusko Deposition Exhibit 303, Levy et al., Multicompartment Pharmacokinetic Models and Pharmacologic Effects, Journal of Pharmaceutical Sciences, 58(4) (1969)
2074	Jusko Deposition Exhibit 306, Mager et al., Scaling Pharmacodynamics from in Vitro and Preclinical Animal Studies to Humans, Drug Metabolism Pharmacokinetics, 24(1): 16-24 (2009)
2075	Jusko Deposition Exhibit 308, Sharma et al., Characterization of Four Basic Models of Indirect Pharmacodynamic Responses, Journal of Pharmacokinetics and Biopharmaceutics, 24(6): 611-635
2076	Jusko Deposition Exhibit 310, Jusko, W. J., Pharmacokinetic Principles in Pediatric Pharmacology, Symposium on Pediatric Pharmacology, Pediatric Clinics of North America, 19(1) (1972)
2077	Shen and Burgess, J. Control Release, 2015 December 10; 219, 644-51
2078	AstraZeneca Pharms. LP v. Anchen Pharms., 2012 US Dist LEXIS 43989 (2012)(unpublished)
2079	Mendyk et al., How-To: Empirical IVIVR without Intravenous Data – Dissolution Technologies May 2015
2080	U.S. Pharmacopeia 24, pp. 1629-1631 (2000)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.